Jefferies Financial Group Reduces Moderna Stake

Institutional investor sells over 32,000 shares of COVID-19 vaccine maker

Published on Mar. 11, 2026

Got story updates? Submit your updates here. ›

Jefferies Financial Group Inc. has reduced its stake in Moderna, Inc. (NASDAQ:MRNA) by 25.3% during the third quarter, according to a recent SEC filing. The fund now owns 95,266 shares of the company's stock after selling 32,310 shares during the period. Jefferies Financial Group's holdings in Moderna were valued at $2.46 million as of its latest SEC disclosure.

Why it matters

Moderna's COVID-19 vaccine has been a major driver of the company's growth and stock performance over the past few years. This reduction in stake by a large institutional investor like Jefferies Financial Group could signal a shift in sentiment around the company and its flagship product.

The details

According to the filing, Jefferies Financial Group sold 32,310 shares of Moderna stock during the third quarter. The firm now owns 95,266 shares of the company's stock, down from 127,576 shares previously. Moderna's stock price has seen significant volatility in recent months, trading between $22.28 and $59.55 over the past 52 weeks.

  • Jefferies Financial Group reduced its Moderna stake during the 3rd quarter of 2026.

The players

Jefferies Financial Group Inc.

A global investment banking firm that provides services to corporations, governments, and high-net-worth individuals.

Moderna, Inc.

A biotechnology company headquartered in Cambridge, Massachusetts that specializes in messenger RNA (mRNA) therapeutics and vaccines, including the widely used COVID-19 vaccine.

Got photos? Submit your photos here. ›

The takeaway

This reduction in Moderna's institutional ownership could signal broader uncertainty around the company's growth prospects and the long-term outlook for its COVID-19 vaccine, which has been a major revenue driver. Investors will be watching to see if other large funds follow suit in trimming their Moderna positions.